Results 11 to 20 of about 50,964 (281)

Novel Strategies for Treating Castration-Resistant Prostate Cancer

Biomedicines, 2021
The development of castration resistance is an inevitable pathway for the vast majority of patients with advanced prostate cancer. Recently, there have been significant breakthroughs in the understanding and management options of castration-resistant ...
David Ka-Wai Leung, Peter Ka-Fung Chiu, Chi-Fai Ng, Jeremy Yuen-Chun Teoh   +3 more
doaj   +2 more sources

Epiregulin expression and secretion is increased in castration-resistant prostate cancer [PDF]

Frontiers in Oncology, 2023
IntroductionIn prostate cancer, long-term treatment directed against androgens often leads to the development of metastatic castration-resistant prostate cancer, which is more aggressive and not curatively treatable.
Marc Wiesehöfer, Benedikt Bernhard Gereon Raczinski, Caroline Wiesehöfer, Jaroslaw Thomas Dankert, Elena Dilara Czyrnik, Martin Spahn, Martin Spahn, Marianna Kruithof-de Julio, Marianna Kruithof-de Julio, Marianna Kruithof-de Julio, Marianna Kruithof-de Julio, Gunther Wennemuth   +11 more
doaj   +2 more sources

Mitoribosome sensitivity to HSP70 inhibition uncovers metabolic liabilities of castration-resistant prostate cancer. [PDF]

, 2023
The androgen receptor is a key regulator of prostate cancer and the principal target of current prostate cancer therapies collectively termed androgen deprivation therapies.
Shrimp, Jonathan H, Maisiak, M, Gestwicki, JE, Nisbet, Ian, Jonathan H Shrimp, Ralph, SJ, Jason E Gestwicki, Murali Krishna Cherukuri, Cherukuri, Murali Krishna, Cherukuri, MK, Shrimp, JH, Marisa Maisiak, Neckers, Leonard M, Maisiak, Marisa, Genesis M Rivera-Marquez, Oleta T Johnson, Ishida, R, Johnson, OT, Echtenkamp, FJ, Rivera-Marquez, Genesis M, Ryo Ishida, Leonard M Neckers, Ishida, Ryo, Sinha, Arnav, Rivera-Marquez, GM, Ralph, Stephen John, Gestwicki, Jason E, Echtenkamp, Frank J, Johnson, Oleta T, Frank J Echtenkamp, Sinha, A, Stephen John Ralph, Ian Nisbet, Nisbet, I, Arnav Sinha, Neckers, LM   +35 more
core   +1 more source

Nonmetastatic Castration-Resistant Prostate Cancer [PDF]

Korean Journal of Urology, 2014
After the introduction of prostate cancer screening with the prostate-specific antigen (PSA) test, we have witnessed a dramatic stage migration. As a result, an increasing number of patients are diagnosed at earlier stages and receive local treatments including surgery or radiation.
Hong, Jun Hyuk, Kim, Isaac Y.
openaire   +2 more sources

Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. [PDF]

PLoS ONE, 2013
Despite advances in detection and therapy, castration-resistant prostate cancer continues to be a major clinical problem. The aberrant activity of stem cell pathways, and their regulation by the Androgen Receptor (AR), has the potential to provide ...
Steven Kregel, Kyle J Kiriluk, Alex M Rosen, Yi Cai, Edwin E Reyes, Kristen B Otto, Westin Tom, Gladell P Paner, Russell Z Szmulewitz, Donald J Vander Griend   +9 more
doaj   +1 more source

Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib. [PDF]

Cancer
Abstract Background The combination of olaparib plus radium‐223 improved progression‐free survival in patients with metastatic castration‐resistant prostate cancer with bone metastases (BM) in the multicenter, randomized, phase 2 COMRADE trial (NCT03317391). Here, the patient‐reported outcome (PRO) analysis of this trial is reported.
McKay RR, Xie W, Ajmera A, Araneta A, Folefac E, Hussain A, Kyriakopoulos CE, Olson A, Parikh M, Parikh R, Saraiya B, Shapiro GI.   +11 more
europepmc   +2 more sources

Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy

IJU Case Reports, 2022
Introduction Treatment strategy for castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy has not been established.
Takahiro Komori, Takeo Kosaka, Keitaro Watanabe, Tomoki Tanaka, Yota Yasumizu, Hiroshi Hongo, Shuji Mikami, Toshio Ohashi, Mototsugu Oya   +8 more
doaj   +1 more source

Nucleoside-Lipid-Based Nanoparticles for Phenazine Delivery: A New Therapeutic Strategy to Disrupt Hsp27-eIF4E Interaction in Castration Resistant Prostate Cancer

Pharmaceutics, 2021
Heat shock protein 27 (Hsp27) has an established role in tumor progression and chemo-resistance of castration-resistant prostate cancer (CRPC). Hsp27 protects eukaryotic translation initiation factor 4E (eIF4E) from degradation, thereby maintaining ...
Hajer Ziouziou, Clément Paris, Sébastien Benizri, Thi Khanh Le, Claudia Andrieu, Dang Tan Nguyen, Ananda Appavoo, David Taïeb, Frédéric Brunel, Ridha Oueslati, Olivier Siri, Michel Camplo, Philippe Barthélémy, Palma Rocchi   +13 more
doaj   +1 more source

The biology of castration-resistant prostate cancer [PDF]

Current Problems in Cancer, 2015
Prostate cancer is one of the most commonly diagnosed cancers and the second leading cause of cancer death in men in the United States. Although there are recently approved therapeutic options for men with advanced and metastatic disease, the unfortunate reality is that advanced prostate cancer is inevitably fatal. Hormonal androgen deprivation therapy
Fei, Lian, Nitya V, Sharma, Josue D, Moran, Carlos S, Moreno   +3 more
openaire   +2 more sources

Calcium phosphate-based nanomedicine mediated CRISPR/Cas9 delivery for prostate cancer therapy

Frontiers in Bioengineering and Biotechnology, 2022
Introduction: Erythropoietin producing hepatocyte receptor A2 (EphA2) is widely presented in the tumor cells, closely related to tumor cell migration, not cell apoptosis and proliferation.
Chao-Gang Wei, Rui Zhang, Lan-Yi Wei, Peng Pan, He Zu, Ya-Zhen Liu, Yong Wang, Jun-Kang Shen   +7 more
doaj   +1 more source